SAN DIEGO – Mirador Therapeutics, Inc. is poised to release safety and efficacy data for multiple clinical-stage drug candidates in 2027, just three years after the company’s founding.
The precision medicine startup expects to give upwards of 10 clinical readouts by the end of next year for the treatment of Crohn’s disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis.
Rather than focusing its resources on just one lead candidate, Mirador aims to reduce its risk of clinical failure by developing multiple drugs with first- and/or best-in-class potential at the same time, according to CEO Mark McKenna.
“At the same time, we view rational combinations and multispecifics as a critical part of the future of innovation in immunology and inflammation,” McKenna stated of the company’s pipeline development. “These approaches have the potential to deliver superior efficacy by targeting synergistic pathways, and they represent an important pillar of our long-term strategy to transform care in these complex diseases.”
‘Human-First’ Approach
Mirador’s drug development pipeline is centered on Mirador360, the company’s discovery platform that uses molecular data from more than 2.5 million patients with inflammation and immunology diseases and machine learning to analyze complex pathways in the immune system that could be vectors for effective drug treatment.
The company’s goal is to shepherd drug candidates from a concept to the submission of an Investigational New Drug application in just 15 months. Mirador expects to file multiple IND applications following its clinical data readouts in 2027.
McKenna argued that the company differentiates itself from other artificial intelligence and machine learning-based drug development companies by combining Mirador360’s outputs with in-house protein engineering and initial biological validation in humans rather than animal models.
“This human-first approach, combined with AI-driven insights and multi-omics datasets, enables better decision-making and accelerates development,” he stated. “Importantly, Mirador360 is designed to identify novel targets and prioritize rational combinations and multispecifics; approaches we believe are essential to delivering step-change efficacy in immunology and inflammation.”
Well-Resourced Clinical Programs
Of course, Mirador is also differentiated by the background of its founders. McKenna and several members of Mirador’s executive team are alumni of Prometheus Biosciences, which Merck & Co. acquired in 2023 for $10.8 billion.
The company initially launched from stealth in 2024 with a $400 million Series A funding round, and followed that by closing a $250 million Series B in the third quarter of 2025, including investment from funds and accounts advised by T. Rowe Price Investment Management, Inc. and Adage Capital Partners L.P.
McKenna avoided giving a firm estimate of how far the investment extends the company’s runway, but indicated that Mirador has the resources to deliver proof-of-concept data across all of its current clinical programs and pursue additional drug candidates.
“Our focus is on disciplined execution and building a category-leading biotech company,” he stated. “As we progress, we’ll continue to evaluate the best ways to support that long-term vision, but right now, our priority is advancing the science and creating durable value.”
Mirador has quickly expanded its presence in San Diego over its first two years, both in footprint and personnel. The company moved into its new headquarters in mid-2025, a 66,000-square-foot facility with state-of-the-art laboratory and office space.
The startup has also grown its staff size from roughly 25 at launch to more than 100 in early 2026.
“Our focus is on building a world-class team across the functions that matter most for advancing our science and delivering on our mission,” McKenna stated. “We are also committed to supporting the vibrant life sciences community in San Diego and growing our employee presence in the area, which we see as an important part of our long-term strategy.”
Mirador Therapeutics, Inc.
FOUNDED: 2024
CEO: Mark McKenna
HEADQUARTERS: San Diego
BUSINESS: Precision medicine development for immune-mediated inflammatory and fi-brotic diseases
EMPLOYEES: Over 100
FUNDING: Over $650 million
WEBSITE: miradortx.com
CONTACT: [email protected]
NOTABLE: Much of Mirador’s executive suite are veterans of Prometheus Biosciences, which Merck & Co. acquired in 2023 for $10.8 billion.
Eli is an award-winning reporter primarily covering the tech and life sciences industries. He previously worked as the San Diego City Hall reporter for the regional wire City News Service. He has also covered public health, transportation and state and local politics in the San Francisco Bay Area for Local News Matters, the nonprofit arm of the regional wire Bay City News Service, where he also oversaw the development and daily content management of the outlet’s public health and COVID-19 news and resource webpage. He is also a contributing writer covering Minor League Baseball for the analysis and commentary website Baseball Prospectus. Eli is a graduate of San Francisco State University and a native of Northern California.
